Login to Your Account



Theravance's $250M in Notes to Pay GSK LABA Milestones

By Catherine Shaffer
Staff Writer

Friday, January 18, 2013
Theravance Inc., of South San Francisco, will use proceeds of a $250 million aggregate principal amount of convertible subordinated notes due 2023 to make milestone payments to GlaxoSmithKline plc upon launch of products developed under the two companies' collaboration around long-acting beta 2 agonists (LABAs).

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription